{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:45:56Z","timestamp":1775598356962,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jgo.2020.09.031","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T04:37:26Z","timestamp":1602304646000},"page":"515-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Electronic FRAIL score may predict treatment outcomes in older adults with myeloma"],"prefix":"10.1016","volume":"12","author":[{"given":"Henry","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yih Harng","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Yee","family":"Seow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Neylon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridgett","family":"McDiarmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jgo.2020.09.031_bb0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16238","article-title":"Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand","volume":"188","author":"Chan","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2020.09.031_bb0010","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/EDBK_239067","article-title":"Approach to the older adult with multiple myeloma","volume":"39","author":"Mina","year":"2019","journal-title":"Am Soc Clin Oncol Edu Book Am Soc Clin Oncolo Ann Meet"},{"issue":"13","key":"10.1016\/j.jgo.2020.09.031_bb0015","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2020.09.031_bb0020","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"suppl_3","key":"10.1016\/j.jgo.2020.09.031_bb0025","doi-asserted-by":"crossref","first-page":"iii20","DOI":"10.1093\/ageing\/afy127.02","article-title":"Assessing the psychometric properties of the his \u201cThink Frailty\u201d tool","volume":"47","author":"Taylor-Rowan","year":"2018","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.jgo.2020.09.031_bb0030","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bjh.16095","article-title":"Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-Centre analysis of real-world data","volume":"187","author":"Chan","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jgo.2020.09.031_bb0035","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2020.09.031_bb0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jgo.2016.02.007","article-title":"Geriatric assessment with management in cancer care: current evidence and potential mechanisms for future research","volume":"7","author":"Magnuson","year":"2016","journal-title":"J Geriatric Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2020.09.031_bb0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/2327-6924.12273","article-title":"A systematic review and comparison of functional assessments of community-dwelling elderly patients","volume":"28","author":"Roedl","year":"2016","journal-title":"J Am Assoc Nurse Pract"},{"issue":"4","key":"10.1016\/j.jgo.2020.09.031_bb0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.NAJ.0000314810.46029.74","article-title":"The Lawton instrumental activities of daily living scale","volume":"108","author":"Graf","year":"2008","journal-title":"Am J Nurs"},{"issue":"1","key":"10.1016\/j.jgo.2020.09.031_bb0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2020.09.031_bb0060","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1200\/JCO.2019.37.15_suppl.8028","article-title":"Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase III ASPIRE and ENDEAVOR","volume":"37","author":"Facon","year":"2019","journal-title":"J Clin Oncol [ASCO Abstract]"},{"issue":"1","key":"10.1016\/j.jgo.2020.09.031_bb0065","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1186\/s12885-018-4807-6","article-title":"Validation of a frailty index in older cancer patients with solid tumours","volume":"18","author":"McCarthy","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2020.09.031_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3545","article-title":"Development and evaluation of a new frailty index for older surgical patients with cancer","volume":"2","author":"Shahrokni","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jgo.2020.09.031_bb0075","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"10.1016\/j.jgo.2020.09.031_bb0080","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2020.09.031_bb0085","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2018-99-116920","volume":"132","author":"Stege","year":"2018","journal-title":"Blood [ASH Abstract]"},{"issue":"9","key":"10.1016\/j.jgo.2020.09.031_bb0090","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/imj.14886","article-title":"Bortezomib use and outcomes for the treatment of multiple myeloma","volume":"50","author":"Loke","year":"2020","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.jgo.2020.09.031_bb0095","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.23933","article-title":"Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study","volume":"90","author":"Mateos","year":"2015","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.jgo.2020.09.031_bb0100","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"How I treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jgo.2020.09.031_bb0105","article-title":"Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines","volume":"10","author":"Manapuram","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.jgo.2020.09.031_bb0110","author":"Zweegman","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jgo.2020.09.031_bb0115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jgo.2020.09.031_bb0120","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the international myeloma working group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2020.09.031_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju067","article-title":"Multiple myeloma in the very old: an IASIA conference report","volume":"106","author":"Tuchman","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jgo.2020.09.031_bb0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(12)70041-4","article-title":"Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England","volume":"13","author":"Lyratzopoulos","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2020.09.031_bb0135","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.jgo.2020.09.031_bb0140","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2019-130079","article-title":"The Spectrum of Exomic mutation in elderly myeloma differs substantially from patients at younger ages consistent with a different evolutionary trajectory to full blown disease based on age of onset","volume":"134","author":"Williams","year":"2019","journal-title":"Blood [ASH Abstract]"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820304586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820304586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:54:10Z","timestamp":1761818050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820304586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1879406820304586"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.09.031","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electronic FRAIL score may predict treatment outcomes in older adults with myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}